Patents by Inventor Katherine A. Fitzgerald

Katherine A. Fitzgerald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Gasdermin D (GSDMD) Succination for the Treatment of Inflammatory Disease
    Publication number: 20230233500
    Abstract: Described herein are compositions and methods for treating inflammation, and inflammation-related conditions, using fumarate or fumarate analogs or inhibitors of fumarate hydratase (FH).
    Type: Application
    Filed: June 11, 2021
    Publication date: July 27, 2023
    Inventors: Katherine A. Fitzgerald, Fiachra Humphries, Paul Thompson
  • TRANSGENIC EXPRESSION OF DNASEI IN VIVO DELIVERED BY AN ADENO-ASSOCIATED VIRUS VECTOR
    Publication number: 20180214576
    Abstract: The disclosure relates to compositions and methods for AAV-mediated delivery of a nuclease to a subject. In some embodiments, the nuclease is DNAse I. In some embodiments, the methods are useful for treatment of lung-associated diseases.
    Type: Application
    Filed: July 28, 2016
    Publication date: August 2, 2018
    Applicant: University of Massachusetts
    Inventors: Katherine A. Fitzgerald, Stefan A. Schattgen, Guangping Gao
  • Intracellular DNA receptor
    Patent number: 8334101
    Abstract: Provided herein are methods of identifying and using compounds that modulate an AIM2 polypeptide-mediated immune response. Further provided herein are methods of treating disease comprising administering to a patient a compound that decreases expression of an AIM2 polypeptide. Further provided herein are methods of providing gene therapy to a patient comprising administering to the patient a gene therapy agent and a compound that decreases expression of an AIM2 polypeptide. In certain embodiments, a compound that decreases expression of an AIM2 polypeptide comprises an siRNA or an shRNA.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: December 18, 2012
    Assignee: University of Massachusetts
    Inventors: Eicke Latz, Veit Hornung, Katherine A. Fitzgerald
  • Intracellular DNA receptor
    Publication number: 20100120894
    Abstract: Provided herein are methods of identifying and using compounds that modulate an AIM2 polypeptide-mediated immune response. Further provided herein are methods of treating disease comprising administering to a patient a compound that decreases expression of an AIM2 polypeptide. Further provided herein are methods of providing gene therapy to a patient comprising administering to the patient a gene therapy agent and a compound that decreases expression of an AIM2 polypeptide. In certain embodiments, a compound that decreases expression of an AIM2 polypeptide comprises an siRNA or an shRNA.
    Type: Application
    Filed: September 25, 2009
    Publication date: May 13, 2010
    Inventors: Eicke Latz, Veit Hornung, Katherine A. Fitzgerald
  • TRIF-related adaptor molecule (TRAM) and uses thereof
    Publication number: 20050158799
    Abstract: A Toll-IL-1-resistance (TIR) domain-containing adaptor-inducing IFN-? (TRIF)-related adaptor molecule (TRAM) has been identified. TRAM acts specifically in the TLR4 signaling pathway. The invention includes compounds useful for modulating TLR signaling by modulating the effects of TRAM.
    Type: Application
    Filed: October 18, 2004
    Publication date: July 21, 2005
    Inventors: Katherine Fitzgerald, Daniel Rowe, Douglas Golenbock